August 2, 2013 (Norfolk, Va.) CIRS will introduce the Stereotactic End-to-End Verification Phantom (STEEV™) at the 55th Annual AAPM Meeting & Exhibition on August 4-8 in Indianapolis.
STEEV is a QA tool for evaluating stereotactic radiosurgery (SRS) system performance during commissioning and daily systems checks. To facilitate patient QA, STEEV serves as a surrogate patient to assess every step of the treatment process- from immobilization and multi-modality imaging (CT, MRI, PET) to thorough treatment plan verification. STEEV’s anthropomorphic, tissue-equivalent design makes it the only phantom to account for the challenging effects of tissue heterogeneity.
SRS is a non-invasive procedure that focuses high doses of radiation to destroy tumor volumes in small areas of the body. The procedure necessitates a high degree of accuracy in target localization and dose delivery, because small errors can result in significant under treatment of portions of the tumor volume or overdose of nearby healthy tissues. By providing challenging system checks, STEEV helps to identify system errors and ultimately leads to better patient outcomes- a key component to CIRS’ company values.
The introduction of STEEV compliments CIRS’ existing suite of site-specific end-to-end QA phantoms, including the Dynamic Thorax Phantom, Dynamic Pelvis Phantom and SBRT Thorax Phantom.
For more information about STEEV and other CIRS products, go to www.cirsinc.com or visit CIRS Booth 1100 at the 55th Annual AAPM Meeting.
CIRS, a Castleray company, is recognized worldwide for tissue simulation technology and is the leader in the manufacture of phantoms and simulators for quantitative densitometry, calibration, quality control and research in the field of medical imaging and radiotherapy. CIRS is headquartered in Norfolk, VA (USA) and distributes products worldwide.
# # #
STEEV is a trademark of Computerized Imaging Reference Systems